Company Overview
About Hemab Therapeutics
Hemab Therapeutics is a rare disease biotechnology company developing treatments for rare bleeding disorders that have no approved prophylactic options. The company raised $157 million in an oversubscribed Series C in October 2025, led by Sofinnova Partners and the Qatar Investment Authority (QIA) — a sovereign wealth fund's direct biotech investment signals strategic medical technology interest alongside financial return.
Business Model & Competitive Advantage
The lead program, sutacimig, targets Glanzmann thrombasthenia (GT) — a rare inherited platelet disorder affecting approximately 1 in 1 million people worldwide where platelets cannot aggregate, causing severe bleeding episodes that are life-threatening and quality-of-life-destroying. Sutacimig is advancing to a registration study in 2026, with a potential FDA filing to follow. There are currently zero approved prophylactic treatments for GT, making any approved therapy in this indication an orphan-drug monopoly with strong pricing power.
Competitive Landscape 2025–2026
Hemab's second program, HMB-003, has an IND filing expected in the first half of 2026, targeting another rare coagulation disorder. QIA's participation reflects Qatar's broader strategy of building a healthcare ecosystem — rare disease biotech acquisitions and partnerships are central to that ambition, and QIA's portfolio companies have typically seen follow-on M&A interest from global pharmaceutical companies.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Hemab Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Hemab Therapeutics has achieved $157M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Hemab Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Hemab Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Hemab Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Hemab Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →